Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Staffurth

Showing results (81-90 of 84) with videos related to

Pageof 9
Sort By:
You have reached the last page of results.This site can display upto 84 results.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
NEJM Evidence|February 6, 2024
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer TreatmentJenny L Donovan, Freddie C Hamdy, J Athene Lane, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Pageof 9

Showing results (81-90 of 84) with videos related to

Sort By:
Pageof 9
You have reached the last page of results.This site can display upto 84 results.
Health Technology Assessment (Winchester, England)|August 11, 2020
Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCTFreddie C Hamdy, Jenny L Donovan, J Athene Lane, et al.
NEJM Evidence|February 6, 2024
Patient-Reported Outcomes 12 Years after Localized Prostate Cancer TreatmentJenny L Donovan, Freddie C Hamdy, J Athene Lane, et al.
Nature Reviews. Clinical Oncology|June 2, 2016
Clinical development of new drug-radiotherapy combinationsRicky A Sharma, Ruth Plummer, Julie K Stock, et al.
Lancet (London, England)|January 1, 2016
Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trialNicholas D James, Matthew R Sydes, Noel W Clarke, et al.
Pageof 9